Claris Ventures
VC Fund
Torino, Italy
Claris Ventures is a venture capital firm focused on early-stage investments in high potential biopharma companies arisen from the Italian R&D ecosystem
- Total investments:
- 17
- Last investment:
- Lead investor:
- 59%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Claris Ventures invests in
Stages Claris Ventures invests in
Countries Claris Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $2.1M–$11M
- Series A
- $6.1M–$23M
- Series B
- $7.4M–$21M
Investment Focus
Industry
- Biotechnology 6 (35%)
- Health Care 3 (18%)
- Life Science 2 (12%)
- Therapeutics 2 (12%)
- Pharmaceutical 2 (12%)
Stage
- Seed 5 (29%)
- Series A 3 (18%)
- Series B 2 (12%)
- Venture - Series Unknown 1 (6%)
Country
- Italy 8 (47%)
- United Kingdom 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ciro Spedaliere
Partner
|
Partner | Total investments: 3 | Find email | |
Barbara Castellano
Investment committee member
|
Investment committee member | Total investments: 7 | Find email | |
Lola Buono
Senior Associate
|
Senior Associate | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lever Bio
|
Lever Bio's vision is to be at the forefront of unlocking groundbreaking advancements in biotech, particularly in the field of immuno-oncology. By fostering strategic collaborations with leading researchers, prestigious universities, and innovative research centers, Lever Bio aims to accelerate the development of cutting-edge therapies andtechnologies | $5.9M / Seed / Dec 22, 2025 | |
|
Lever Bio
|
Lever Bio's vision is to be at the forefront of unlocking groundbreaking advancements in biotech, particularly in the field of immuno-oncology. By fostering strategic collaborations with leading researchers, prestigious universities, and innovative research centers, Lever Bio aims to accelerate the development of cutting-edge therapies andtechnologies | $4.5M / Seed / May 28, 2025 | |
Iama Therapeutics
|
At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need. | $17.1M / Venture - Series Unknown / Apr 16, 2025 | |
NeoPhore
|
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms,enabling cancer patients to get treated and achieve improved clinical outcomes. | $12.2M / Series B / Feb 01, 2024 | |
Resalis Therapeutics
|
Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche | $10.9M / Series A / Jan 04, 2024 | |
ALKemist Bio
|
ALKemist Bio provides cell treatment to cancer patients. | $7.6M / Seed / Dec 21, 2023 | |
|
ALKemist Bio
|
ALKemist Bio provides cell treatment to cancer patients. | $7.6M / Seed / Dec 21, 2023 | |
Repron Therapeutics
|
Repron Therapeutics provides treatments for solid tumor cases where radical excision is not possible and metastasis or recurrence is extremely likely. | $2.1M / Seed / Jun 06, 2023 | |
|
Repron Therapeutics
|
Repron Therapeutics provides treatments for solid tumor cases where radical excision is not possible and metastasis or recurrence is extremely likely. | $2.1M / Seed / Jun 06, 2023 | |
|
Resalis Therapeutics
|
Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche | $10.6M / Seed / Feb 22, 2023 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Claris Ventures invest in?
Claris Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 17 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Claris Ventures's check size?
Claris Ventures typically joins rounds of $2.1M–$11M at Seed, $6.1M–$23M at Series A and $7.4M–$21M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Claris Ventures participates in.
How do I contact Claris Ventures?
Public channels for Claris Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Claris Ventures?
The team at Claris Ventures includes Ciro Spedaliere (Partner), Barbara Castellano (Investment committee member) and Lola Buono (Senior Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
